Human Genome Shareholders Say GSK's $3B Offer Too Low
Just two weeks after announcing its drawn-out $3 billion takeover of U.S. biotech company Human Genome Sciences Inc., British drugmaker GlaxoSmithKline PLC was hit Monday with a putative class action from...To view the full article, register now.
Already a subscriber? Click here to view full article